A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Dasiglucagon (Primary) ; Glucagon; Insulin glulisine
- Indications Hypoglycaemia
- Focus Registrational; Therapeutic Use
- Sponsors Zealand Pharma
- 01 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 May 2018 According to a Zealand Pharma media release, all patients have been enrolled and dosed in this trial and results are expected in Q3 2018.
- 02 May 2018 Planned End Date changed from 31 Aug 2018 to 15 Jun 2018.